Payment overview · 2025
General Payments
$36,239.40
197 reported records · 15 companies
Healthcare provider profile · identity verified
Robert S Meadows, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · WINSTON SALEM, NC · NPI 1386667343
Verified facts
What the public records show
CMS Open Payments records show Robert S Meadows, MD received $36,239.40 in general payments during 2025 across 197 reported records.
Lilly USA, LLC accounted for 92.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Botox, Ingrezza, Nurtec Odt, Qulipta, Ubrelvy, Ultomiris, Vyvgart Hytrulo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ubrelvy by this doctor in 2024.
ARGENX US, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYVGART HYTRULO as an associated drug or biological on 16156 records involving 4992 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vyvgart Hytrulo by this doctor in 2024.
Alexion Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ULTOMIRIS as an associated drug or biological on 24281 records involving 10608 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ultomiris by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REYVOW as an associated drug or biological on 378 records involving 290 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Reyvow by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Nurtec Odt by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33,372.27 | 92.1% | 47 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $693.31 | 1.9% | 14 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $527.80 | 1.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $517.71 | 1.4% | 52 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $466.24 | 1.3% | 33 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $222.73 | 0.6% | 25 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $158.22 | 0.4% | 15 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.62 | 0.2% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $55.60 | 0.1% | 2 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $36.65 | 0.1% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $28.15 | 0.1% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $22.64 | 0.1% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $18.87 | 0.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $18.36 | 0.1% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $15.23 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $32,016.64 | 33 |
| Food and Beverage | $2,805.00 | 156 |
| Travel and Lodging | $1,352.62 | 6 |
| Education | $65.14 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $33,189.67 | 46 | 2025 |
Source payment records
|
|||||
| Vercise Normalized: vercise |
Device | Boston Scientific Corporation | $527.80 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $446.65 | 47 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $429.57 | 46 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $405.84 | 27 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $222.73 | 25 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $206.39 | 24 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $125.01 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $85.62 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $69.21 | 4 | 2025 |
Source payment records
|
|||||
| Apokyn Normalized: apokyn |
Drug | MDD US Operations, LLC | $65.39 | 6 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $60.40 | 6 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $55.60 | 2 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $36.65 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $35.85 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $28.15 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| Xadago Normalized: xadago |
Drug | MDD US Operations, LLC | $20.94 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| BOTOX botox |
2025 | Botox | 2024 | 73 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 110 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ULTOMIRIS ultomiris |
2025 | Ultomiris | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VYVGART HYTRULO vyvgart hytrulo |
2025 | Vyvgart Hytrulo | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
73 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ARGENX US, INC. Exact reporting entity; no affiliate inference |
2025 | VYVGART HYTRULO open payments reported associated product |
CMS Open Payments — General Payments 16156 supporting records · 4992 recipient NPIs · example record 1240416058 |
Vyvgart Hytrulo · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Alexion Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | ULTOMIRIS open payments reported associated product |
CMS Open Payments — General Payments 24281 supporting records · 10608 recipient NPIs · example record 1202912926 |
Ultomiris · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | REYVOW open payments reported associated product |
CMS Open Payments — General Payments 378 supporting records · 290 recipient NPIs · example record 1186470979 |
Reyvow · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
110 | 22 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 434 | 103 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 336 | 78 |
| Clonazepam | Clonazepam | 250 | 48 |
| Primidone | Primidone | 243 | 67 |
| Levetiracetam | Levetiracetam | 229 | 51 |
| Donepezil Hcl | Donepezil Hcl | 226 | 57 |
| Memantine Hcl | Memantine Hcl | 226 | 56 |
| Pregabalin | Pregabalin | 222 | 41 |
| Ropinirole Hcl | Ropinirole Hcl | 213 | 49 |
| Rivastigmine | Rivastigmine Tartrate | 182 | 35 |
| Alprazolam | Alprazolam | 171 | 24 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 167 | 46 |
| Trazodone Hcl | Trazodone Hcl | 114 | 27 |
| Nurtec Odt | Rimegepant Sulfate | 110 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 109 | 26 |
| Sertraline Hcl | Sertraline Hcl | 105 | 20 |
| Mirtazapine | Mirtazapine | 100 | 25 |
| Emgality Pen | Galcanezumab-Gnlm | 92 | 13 |
| Aimovig Autoinjector | Erenumab-Aooe | 88 | suppressed |
| Lamotrigine | Lamotrigine | 88 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 83 | 19 |
| Botox | Onabotulinumtoxina | 73 | 27 |
| Baclofen | Baclofen | 72 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 19 |
| Prednisone | Prednisone | 69 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 20 |
| Nuplazid | Pimavanserin Tartrate | 60 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 60 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 13 |
| Topiramate | Topiramate | 60 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 53 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 53 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 11 |
| Meloxicam | Meloxicam | 48 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 14 |
| Lorazepam | Lorazepam | 44 | 15 |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 42 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 40 | 12 |
| Ubrelvy | Ubrogepant | 39 | suppressed |
| Ingrezza | Valbenazine Tosylate | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 37 | suppressed |
| Carbamazepine | Carbamazepine | 32 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 32 | suppressed |
| Modafinil | Modafinil | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Amantadine | Amantadine Hcl | 30 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 30 | suppressed |
| Lacosamide | Lacosamide | 30 | suppressed |
| Qulipta | Atogepant | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Dalfampridine Er | Dalfampridine | 27 | suppressed |
| Kesimpta Pen | Ofatumumab | 27 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | 11 |
| Zonisamide | Zonisamide | 25 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Austedo Xr | Deutetrabenazine | 23 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Austedo | Deutetrabenazine | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 20 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 20 | suppressed |
| Teriflunomide | Teriflunomide | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 18 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Fingolimod | Fingolimod Hcl | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 17 | suppressed |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 16 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 16 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 15 | suppressed |
| Xcopri | Cenobamate | 15 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 14 | suppressed |
| Keppra | Levetiracetam | 14 | suppressed |
| Omeprazole | Omeprazole | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Quviviq | Daridorexant Hcl | 14 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 13 | suppressed |
| Lisinopril | Lisinopril | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Nourianz | Istradefylline | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Reyvow | Lasmiditan Succinate | 12 | suppressed |
| Ultomiris | Ravulizumab-Cwvz | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Vyvgart Hytrulo | Efgartigimod-Hyaluronidas-Qvfc | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $36,239.40 · 197 records | Lilly USA, LLC | AJOVY, AMYVID, AUSTEDO XR, Apokyn, BOTOX, CREXONT, EPIDIOLEX, INGREZZA, KISUNLA, Mavenclad, NURTEC ODT, QULIPTA, Rystiggo, UBRELVY, ULTOMIRIS, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VYVGART HYTRULO, Vercise, Xadago, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error